SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 185.01-1.8%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (21189)5/19/1998 10:20:00 PM
From: Andrew H  Read Replies (1) of 32384
 
The dose limiting toxicity results on 1550 were extremely impressive.

However, I was a bit concerned about the side effect profile of Panretin (oral, I think) recently released. I know the subjects were taking a variety of other drugs but wouldn't baseline have been measured including those drugs? In which case Panretin or Panretin interactions would be largely responsible for the side effects?

I guess its hard to say much when the patients' immune systems are so heavily comprimised.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News